glp 1 for chronic kidney disease GLP1 Receptor Agonists vs SGLT2-I in Preventing CKD in T2DM: An Interview – AJKD Blog Glucagon-like peptide 1(GLP-1) receptor agonists

It's just more work

Side Effects of Qsymia for Weight Loss The most common side effects, reported by 5% or more of patients, include: Paresthesia (tingling in hands, feet, or face), reported by about 20% of patients Dry mouth Insomnia , especially if taken later in the day Dizziness Constipation Taste changes , particularly with carbonated drinks Mood changes , including irritability or low mood Difficulty concentrating or brain fog with higher doses of topiramate Less common but more serious risks include: Increased heart rate Acute glaucoma (rare, but requires immediate discontinuation) Kidney stones Birth defects (Qsymia is in a Risk Evaluation and Mitigation Strategy or REMS program, due to teratogenicity risk) Qsymia should not be used during pregnancy, in patients with glaucoma, hyperthyroidism or those taking MAOIs

A study published in Frontiers in Endocrinology advised that, since both oral and injectable semaglutide are effective, the choice between them should be based on individual preferences, convenience and specific health needs, ensuring the treatment best aligns with the patients lifestyle

Perhaps, satiety is met earlier via GLP-1 drugs